Factors Driving the Autoimmune Disease
Diagnostic Market
Blue Earth
Diagnostics is a leading molecular imaging
diagnostics company focussed on the development and commercialisation of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need.
The most common cancer
diagnostic methods are biopsy, sentinel node biopsy, endoscopy, blood tests, bone marrow aspiration, Pap test, sputum and bronchial washing analysis, imaging studies, genetic analysis, etc.
In addition to the biological and logistic limitations of traditional companion
diagnostics, the economic implications for using single biomarker assays are becoming more significant as reimbursement for high-complexity laboratory tests continues to decrease.
Changes in the
diagnostic plot can indicate shifts in the liquid to gas flow rate ratio, and the
diagnostics are also good at monitoring the health of each DP transmitter.
Molecular
Diagnostics focuses on developing predictive tools that can assist in patient prognosis and treatment.
This chapter also focuses on opportunities for public sector partnerships to defray costs, ease evaluation and assist market entry for improved
diagnostics.
For many providers of research products for nucleic acid analysis technologies other than PCR, the molecular
diagnostics market represents a new market opportunity, for which their technology platforms can be utilized by providers of molecular
diagnostics assays to create new clinical
diagnostic tests.
It has not been cleared or approved by authorities including the United States Food and Drug Administration or any other regulatory agency in the United States, or under the European IVD Directive, for human
diagnostic or other clinical use, and is not intended and should not be used for human
diagnostic or any other clinical purposes.
Customers and competitors identified a large number of alternative immunochemistry test firms in a position to replace Siemens and Bayer
Diagnostics in case of price increases.
IVAX
Diagnostics, Inc.(AMEX:IVD), Miami, Fla., has reported its financial results for the first quarter of 2005.
